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XDiscussion
Dr Jonathan Chen (New York, NY). I would like to congratu-
late Dr Karamichalis and colleagues from the Denver Children’s
Hospital on an impressive series from one of the leading centers
for pediatric heart transplantation in North America.
While survival following transplantation continues to improve,
regrettably a sizable minority of these recipients will require re-
transplantation and, in this way, transplantation is for many chil-
dren a palliative procedure that merely postpones an inevitable
graft replacement anywhere from several years to several decades
following the primary operation.
Our findings at Columbia have mirrored those of Denver, sug-
gesting that the survival outcomes following retransplantation
are now comparable to primary transplantation in well-selected
candidates. The report today seeks to further characterize this sub-
cohort of retransplant candidates with a particular interest on the
age at their primary procedure.
Having had, thank you, the benefit to review your data prior to
this presentation, I have 4 questions for the authors.
The first is: Were there any children with graft failure who were
not deemed retransplant candidates during your study period and
thus did not make it into this study?
Dr Karamichalis.We had patients whowere listed on the wait-
ing list for retransplantation. We had 10 patients who were listed
for retransplantation: 5 of them died on the transplant list, 2 of
them were transferred to another facility, and 3 of them were re-
moved from the list because their condition improved.
Dr Chen. Second, how was the decision made to divide these
patients into groups that were greater than and less than 1 year
of age? Inferences from ABO-incompatible strategies would sug-
gest that the time of so-called immunologic privilege can extend as
far as 14 months or longer.
Dr Karamichalis. Because of the known immaturity of the in-
fant immune system, we felt that the infant recipient population
would have an advantage over anybody over 1-year-old, so we di-
vided the groups into less than 1 year or over 1 year. The ISHLT
database registry divides these patients into more than 2 sub-The Journal of Thoracic and Cagroups; however, because of our small group, we decided to
draw the line between infants and older than 1.
DrChen.Third, I’m somewhat perplexed still at the finding that
there is more transplant coronary disease but fewer incidences of
rejection in your infant subcohort. And I wonder whether some
of this could be due to the differences in surveillance that you de-
scribewith respect to your age-based protocols that dictate the tim-
ing of the endomyocardial biopsies.
Dr Karamichalis. The data concerning the short follow-up of
those 5 patients corresponds to the time after retransplantation.
All patients that had their first transplant and made it to retrans-
plantation had surveillance angiograms at the first anniversary of
their transplant and subsequently every other year. If there was ev-
idence of CAV, then they would receive more frequent surveillance
for CAV and treatments.
At the time of catheterization, all patients also had endomyocar-
dial biopsies. So given the median graft survival of both the infant
and the older group, the older being 3.9 years, then all of those pa-
tients should have at least had 2 or 3 endomyocardial biopsies and
at least 3 angiograms.
Dr Chen. Do you know if it’s the practice to treat episodes of
transplant coronary disease in the absence of rejection? So could
it be that the coronary disease was detected in the infants and
they were treated before there was biopsy-proven rejection and
thus the lower incidence of rejection?
Dr Karamichalis. Once CAV is diagnosed in these patients at
our center, they get treated. And the strategy that we use, includes
statins or antilipid agents, we also use MMF and rapamycin, an
antiproliferative agent, to decelerate the progression of CAV in
these patients. So any evidence or any signs of CAV, no matter
how severe or mild they might be, they get treated. The treatment
escalates based on the severity of the CAV.
Dr Chen. Finally, is it possible that the decreased graft survival
and increased rejection in your group 2 was related to medication
noncompliance, given that the fact that the average age of this
group was 9, plus or minus 6 years, at their primary transplant,
which would render many of them medically recalcitrant adoles-
cents at the time of their initial post-transplant years.
Dr Karamichalis. I think that’s an excellent point and it’s defi-
nitely something worth mentioning. In the older population, there
may be a compliance issue of which we are not aware. Even though
we discussed it, we haven’t really searched specifically for noncom-
pliance in these patients, but it’s definitely something that is well
known to cause rejection inpatientswhodon’t take theirmedications.
Dr Chen. Thanks. These are very provocative and very interest-
ing data. I’m very interested in how these findings play out as you
follow these patients postretransplant.
Dr Carl Backer (Chicago, Ill). John, congratulations on a very
nice analysis. Clearly, this is a huge amount of work.
I have a question. Given the data that you have on retransplanta-
tion, I’d like to ask your opinion about 2 high-risk groups. The first
is the patient who has had their first transplant, doesn’t come off by-
pass because they have right ventricular dysfunction, and now
you’re contemplating whether or not you should relist them for an-
other transplant. Did you have any patients like that in your series
and what are your thoughts about that population group?
Dr Karamichalis. Thank you for your comments and your
question.rdiovascular Surgery c Volume 141, Number 1 229
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XNo,wedid not have any relisting of early graft failure.One patient
retransplantedwasmore than a year after his primary transplant. Ev-
erybody else got retransplanted at 2 ormore years after their primary
transplant. So I do not believewe have anybody that was relisted fol-
lowing primary transplantation with failure to come off bypass.
Dr Backer. The second question is: What do you think about
a third-time transplant? Do you have any patients who you’ve
transplanted a third time and what’s your opinion about that?230 The Journal of Thoracic and Cardiovascular SurgDr Karamichalis. I’m aware of 1 patient who was offered
third-time retransplantation. That patient refused to be relisted
and died subsequently of PTLD, which was unrelated to CAV or
rejection. I know other centers have reported third-time retrans-
plantations. I guess it would be a collective decision between ev-
erybody involved. And, if somebody makes a compelling case,
then a third transplant should be offered but it would only be on
a case-to-case basis.ery c January 2011
